Low-dose cyclosporin A microemulsion in children with severe atopic dermatitis: clinical and immunological effects

Area of Science:

• Immunology
• Dermatology
• Pediatrics

Background:

• Severe childhood atopic dermatitis (AD) presents significant challenges.
• Cyclosporin A (CsA) is an established treatment, but safety concerns exist, particularly regarding dosing in children.
• Optimizing CsA dosage for pediatric AD is crucial for balancing efficacy and safety.

Purpose of the Study:

• To evaluate the clinical efficacy of low-dose Cyclosporin A (CsA) in treating severe childhood atopic dermatitis (AD).
• To assess the impact of low-dose CsA on T-cell dysregulation in pediatric AD patients.
• To determine the safety and tolerability profile of initiating CsA at a low dose for severe childhood AD.

Main Methods:

• An open prospective study involving 10 children with severe AD (mean objective SCORAD > 40).
• Treatment with CsA solution, starting at 2.5 mg/kg/day and increasing stepwise to a maximum of 5 mg/kg/day for non-responders, over 8 weeks.
• Disease activity assessed via SCORAD index; T-cell cytokine production and numbers analyzed using intracellular cytokine staining and fluorescence-activated cell sorter (FACS) analysis.

Main Results:

• Nine out of ten patients achieved at least a 35% reduction in SCORAD scores.
• Seven responders achieved significant improvement with CsA doses of 2.5 mg/kg/day or 3.5 mg/kg/day.
• CsA treatment led to a significant reduction in key cytokine-producing T lymphocytes (IL-4, IL-13, IFN-gamma, IL-2) and HLA-DR-positive CD3(+) cells.

Conclusions:

• Low-dose initiation of Cyclosporin A (CsA) microemulsion is effective in improving clinical measures of severe pediatric atopic dermatitis (AD).
• This therapeutic approach successfully reduces T-lymphocyte cytokine production and regulates T-cell activation in children with severe AD.
• Starting CsA at 2.5 mg/kg/day offers a safer and effective strategy for managing severe childhood AD.